Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.84 |
| ▸ | MAPT | P10636 | 8/20 | 0.84 |
| ▸ | HPGD | P15428 | 7/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.84 |
| ▸ | TP53 | P04637 | 5/20 | 0.84 |
| ▸ | MAOA | P21397 | 5/20 | 0.84 |
| ▸ | MAOB | P27338 | 5/20 | 0.84 |
| ▸ | MEN1 | O00255 | 4/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.84 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.84 |
| ▸ | BCL2 | P10415 | 1/20 | 0.84 |
| ▸ | IL2 | P60568 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 10/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formononetin SCHEMBL29361145 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| Formononetin SCHEMBL62915 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| Formononetin SCHEMBL15271536 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| Formononetin SCHEMBL6638953 | 0.91 | KDM4E (0.97) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| Formononetin SCHEMBL8416577 | 0.91 | KDM4E (0.97) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| Daidzein SCHEMBL2025991 | 0.89 | KDM4E (0.86) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL73754 | 0.87 | ALDH1A1 (0.70) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| 7-Hydroxy Isoflavone SCHEMBL5803559 | 0.85 | KDM4E (0.94) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| 7-Hydroxy Isoflavone SCHEMBL762528 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL4175335 | 0.85 | KDM4E (0.86) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210010056-A1 | GLYCOSYLATION MODIFICATION OF BIOACTIVE COMPOUNDS AND DRUGS BY PLANT GLYCOSYLTRANSFERASES (UGTS) | UNIV NORTH TEXAS (US) | 2021-01-14 | — | — | US | claimed |
| EP-0979074-A4 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | NOVOGEN INC (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020035074-A1 | Treatment or prevention of menopausal symptoms and osteoporosis | NOVOGEN, INC. | 2002-03-21 | — | — | US | claimed |
| US-6340703-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ISOFLAVONE FORMONONETIN | NOVOGEN, INC. | 2002-01-22 | — | — | US | claimed |
| EP-0979074-A1 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | Novogen Inc. (US) | 2000-02-16 | — | — | EP | claimed |
| WO-1998050026-A1 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | NOVOGEN INC (US) | 1998-11-12 | — | — | WO | claimed |
| US-11730778-B2 | Method of increasing the level and production of metabolized phytonutrients in a subject | ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230233626-A1 | METHOD AND COMPOSITION FOR PRODUCTION OF A PHYTONUTRIENT IN A MICROBIOME | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2023-07-27 | — | — | US | disclosed |
| CN-114423420-A | Methods and compositions for producing phytonutrients in microbiome | 捷通国际有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2021061712-A1 | METHOD AND COMPOSITION FOR PRODUCTION OF A PHYTONUTRIENT IN A MICROBIOME | ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210085732-A1 | METHOD AND COMPOSITION FOR PRODUCTION OF A PHYTONUTRIENT IN A MICROBIOME | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2021-03-25 | — | — | US | disclosed |
| US-20210010056-A1 | GLYCOSYLATION MODIFICATION OF BIOACTIVE COMPOUNDS AND DRUGS BY PLANT GLYCOSYLTRANSFERASES (UGTS) | UNIV NORTH TEXAS (US) | 2021-01-14 | — | — | US | disclosed |
| WO-2001058262-A1 | METHODS OF INDUCING PRODUCTION OF ISOFLAVONES IN PLANTS USING NUCLEAR RECEPTOR LIGANDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-0979074-A1 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | Novogen Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0979074-A1 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | Novogen Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1999021006-A9 | PHARMACEUTICAL GRADE VALERIAN, BLACK COHOSH, VITEX AGNUS-CASTUS, BILBERRY AND MILK THISTLE | PHARMAPRINT INC (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999021006-A1 | PHARMACEUTICAL GRADE VALERIAN, BLACK COHOSH, VITEX AGNUS-CASTUS, BILBERRY AND MILK THISTLE | PHARMAPRINT, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998050026-A1 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | NOVOGEN INC (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050026-A1 | TREATMENT OR PREVENTION OF MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS | NOVOGEN INC (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035074-A1 | Treatment or prevention of menopausal symptoms and osteoporosis | VDR, CYP19A1, SHBG | KDM4E 4396/4885ALDH1A1 4712/4885SMN1; SMN2 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.